Nanjing Leads Biolabs Files for Hong Kong IPO Amid Product Pipeline Progress
China-based Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotech company focusing on oncology and autoimmune...
Company
Acotec Scientific Gains NMPA Approval for AcoArt Verbena Vertebral Balloon
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has received marketing approval from China’s National Medical...
Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Study of SHR-A1811, Adebrelimab and Famitinib in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
Qure Biotechnology Secures RMB 100 Million Series C1 Financing
China-based Qure Biotechnology (Shanghai) Co., Ltd. announced the completion of a Series C1 financing round...
Lianhuan Pharma Gains NMPA Approval for No-Spa Generic
China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) announced that it has received market clearance...
Roche’s Evrysdi 5mg Tablet Gains EU Commission Approval for Spinal Muscular Atrophy
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has...
Shanghai OPM Biosciences Plans Acqusition of PharmaLegacy Labs for RMB 1.45 Billion
Shanghai OPM Biosciences Co., Ltd (SHA: 688293), a China-based cell culture-focused Contract Development and Manufacturing...
Sunshine Guojian’s SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...
Intragrand Pharma Licenses Lenamilast to Transpire Bio for Global Development
China-based Suzhou Intragrand Pharma has entered into a licensing agreement with U.S.-headquartered Transpire Bio Inc....
Consun Pharma Partners with DP Technology to Accelerate AI-Driven Kidney Disease Drug R&D
China-based Consun Pharmaceutical Group Ltd (HKG: 1681) announced a strategic partnership with compatriot firm DP...
Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE
China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion...
BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes
US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received an indication extension...
Shanghai Pharma Partners with Chugai Pharma China to Enhance Bone Health Products
China’s Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607; SPH) has established a partnership...
Genrix Bio Partners with Cullinan Therapeutics for GR1803 License
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,...
AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) received approval from China’s National Medical Products Administration...
Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication
China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the...
Salubris Pharmaceuticals’ Allisartan-Indapamide Hybrid Wins NMPA Approval
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, announced that it has...
Wantai Biopharm’s Cecolin 9 HPV Vaccine Approved by China’s NMPA
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its 9-valent human...
Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials
Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that...
NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination
Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013)...